Print Email  

What We Are Funding

Today we find ourselves poised at an incredible crossroads in Duchenne. We are proud of our investments in research and that the Duchenne pipeline is so rich with promise. In total, PPMD has invested over $45 million into Duchenne research which has leveraged over $500 million in additional funding.

PPMD continues to drive change in the research arena. Our grant cycles offer opportunities to investigators and help us keep our finger on the pulse of research. PPMD’s Scientific Advisory Board expertly reviews every grant that comes in and offers funding or advice on how to proceed to garner funding in the future. Our collaboration with academic research institutes and industry partners helps us push potential treatments to clinic faster, which in turn provides access to the Duchenne community and patients faster.

We don’t just look at one problem, or one bit of research, but rather we are looking comprehensively at the entire landscape and trying to intercept areas where time could be lost and opportunities missed. We invest in research that will impact every person touched by Duchenne, no matter their age, stage of progression, or mutation.

Our Funding Portfolio highlights new treatments and therapies at various stages of development. Your support can turn their promise into success.


modal-donate.jpg

Current Projects Needing Funding

 

YEAR TITLE RECIPIENT TYPE AMOUNT
2014 Single AON-induced multiple exon skipping in the mdx(Cv5) mouse model Dr. Judith van Deutekom, Prosensa Research Grant $200,000
2014 Aptamer-based serum biomarker profiling in DMD longitudinal samples Dr. Annemieke Aartsma-Rus, LUMC Research Grant $49,300
2014 Predicting the benefit vs the side effects of corticosteroids in Duchenne muscular dystrophy Dr. Robert Griggs, University of Rochester Research Grant $78,357
2013 Preclinical testing of procysteine for reducing dystropathology in the mdx mouse model of Duchenne Muscular Dystrophy Dr. Peter Arthur, University of Western Australia Exploratory Grant $49,998
2013 Early Treatment with Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy- 2 year extension trial Dr. Subha Raman, Cincinnati Children's Hospital Medical Center Investigator Grant $52,500
2013 microRNAs as a modifier of exon skipping efficacy: feasibility of co-delivery Dr. Erica Reeves, Reveragen Exploratory Grant $49,991
2012 Pilot Project to identify genetic modifiers of Duchenne muscular dystrophy Dr. Stanley Nelson, University of California, Los Angeles Research Grant $100,000
2012 Exons 45-55 skipping with a cocktail antisense oligo Dr. Toshifumi Yokota, University of Alberta Research Grant $50,000
2012 Long-term efficacy and side effect profile of compound A, a selective glucocorticoid receptor modulator in mdx mice Dr. Kanneboyina Nagaraju, Children’s Research Institute Research Grant $50,000
2012 Development of MEMRI as an outcome measure for pre-clinical studies in the mdx mouse Dr. Volker Straub, University of Newcastle Upon Tyne Research Grant $49,003
2012 Magnetic Resonance Imaging as a Biomarker in Muscular Dystrophy Supplement Dr. Kristen Vandenborne, University of Florida Research Grant $59,598
2012 Clinically Meaningful Outcomes for Duchenne Muscular Dystrophy Therapeutic Trials Dr. Erik Henricson, University of California, Davis Research Grant $175,000
2012 Early treatment with Aldosterone antagonism attenuates cardiomyopathy in Duchenne MD (Epleronone Trial) Dr. Kan Hor, Cincinnati Children's Hospital Medical Center Research Grant $84,092

 

View our full Funding Portfolio

 

 

In this section

Funding Portfolio
Programs & Priorities
Review Committees 

Connects
Facebook YouTube Twitter
How We Help



Our family-centered approach is at the heart of everything we do. Learn more.

Quick Links

Fund Research

Quick Links
PPMD Sites

new amazon banner small inner pages

]]